A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo.
We tried to induce tumor cell death in vivo through Fas (CD95)-mediated apoptosis. Murine hepatoma MH 134 (Fas-) was transfected with murine Fas antigen cDNA. Fas+ F6b but not Fas- N1d cells underwent apoptosis after treatment with anti-Fas antibody in vitro. The possibility of eradicating tumor cells in vivo with anti-Fas antibody was investigated using double-mutant gld/gld lpr/lpr mice which lack both Fas ligand (FasL) and Fas to avoid cytotoxic activity of the antibody to the liver and interference from endogenous FasL. A single administration of anti-Fas antibody efficiently suppressed the growth of F6b tumors but not that of N1d tumors in these mice. Thus, the therapy with Fas-FasL system may be a promising approach for cancer treatment, and this model is useful for study on in vivo apoptosis-mediated antitumor activity.
Shimizu
M
M
Department of Cancer Therapeutics, Tokyo Metropolitan Institute of Medical Science, Japan.
Yoshimoto
T
T
Nagata
S
S
Matsuzawa
A
A
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use* / Q000633:toxicity; D017209:Apoptosis; D002470:Cell Survival; D007167:Immunotherapy; D008114:Liver Neoplasms, Experimental / Q000473:pathology* / Q000628:therapy; D051379:Mice; D008809:Mice, Inbred C3H; D008817:Mice, Mutant Strains; D011994:Recombinant Proteins / Q000378:metabolism; D014162:Transfection; D014407:Tumor Cells, Cultured; D019014:fas Receptor / Q000096:biosynthesis / Q000276:immunology / Q000502:physiology*
D000906:Antibodies; D011994:Recombinant Proteins; D019014:fas Receptor